Hilde Omholt

906 total citations
7 papers, 689 citations indexed

About

Hilde Omholt is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Hilde Omholt has authored 7 papers receiving a total of 689 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 4 papers in Oncology and 1 paper in Hematology. Recurrent topics in Hilde Omholt's work include Immunotherapy and Immune Responses (7 papers), T-cell and B-cell Immunology (6 papers) and Immune Cell Function and Interaction (3 papers). Hilde Omholt is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), T-cell and B-cell Immunology (6 papers) and Immune Cell Function and Interaction (3 papers). Hilde Omholt collaborates with scholars based in Norway, Switzerland and Sweden. Hilde Omholt's co-authors include Peter O. Hofgaard, Bjarne Bogen, Alexandre Corthay, Katrin U. Lundin, Egil Røsjø, Guttorm Haraldsen, Zlatko Dembić, Ludvig A. Munthe, Marte Fauskanger and Kristina Berg Lorvik and has published in prestigious journals such as Blood, Immunity and Frontiers in Immunology.

In The Last Decade

Hilde Omholt

7 papers receiving 682 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hilde Omholt Norway 6 579 384 131 52 44 7 689
Jeannette Cany Netherlands 15 460 0.8× 376 1.0× 119 0.9× 89 1.7× 28 0.6× 20 632
Thierry Connerotte Belgium 11 533 0.9× 291 0.8× 224 1.7× 32 0.6× 35 0.8× 14 629
Ashley Knights Australia 13 498 0.9× 322 0.8× 269 2.1× 47 0.9× 21 0.5× 15 705
Kevin M. Friedman United States 8 283 0.5× 405 1.1× 193 1.5× 67 1.3× 29 0.7× 15 530
Korina G. Veenstra United States 6 317 0.5× 216 0.6× 139 1.1× 25 0.5× 38 0.9× 8 484
Susanne Wilde Germany 13 430 0.7× 345 0.9× 142 1.1× 28 0.5× 24 0.5× 20 542
Peter Hinderlie United States 14 769 1.3× 531 1.4× 96 0.7× 90 1.7× 74 1.7× 23 878
Cornelia Hyatt United States 10 458 0.8× 325 0.8× 128 1.0× 39 0.8× 57 1.3× 16 597
Erlend Strønen Norway 5 370 0.6× 339 0.9× 148 1.1× 25 0.5× 68 1.5× 7 463
Tania F. Rowley United Kingdom 12 579 1.0× 232 0.6× 123 0.9× 21 0.4× 77 1.8× 13 701

Countries citing papers authored by Hilde Omholt

Since Specialization
Citations

This map shows the geographic impact of Hilde Omholt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilde Omholt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilde Omholt more than expected).

Fields of papers citing papers by Hilde Omholt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilde Omholt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilde Omholt. The network helps show where Hilde Omholt may publish in the future.

Co-authorship network of co-authors of Hilde Omholt

This figure shows the co-authorship network connecting the top 25 collaborators of Hilde Omholt. A scholar is included among the top collaborators of Hilde Omholt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilde Omholt. Hilde Omholt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Haabeth, Ole Audun Werner, Anders Tveita, Marte Fauskanger, et al.. (2014). How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?. Frontiers in Immunology. 5. 174–174. 152 indexed citations
2.
Corthay, Alexandre, Katrin U. Lundin, Egil Røsjø, et al.. (2005). Primary Antitumor Immune Response Mediated by CD4+ T Cells. Immunity. 22(3). 371–383. 346 indexed citations
3.
Dembić, Zlatko, Peter O. Hofgaard, Hilde Omholt, & Bjarne Bogen. (2004). Anti‐Class II Antibodies, but not Cytotoxic T‐Lymphocyte Antigen 4–Immunoglobulin Hybrid Molecules, Prevent Rejection of Major Histocompatibility Complex Class II‐Negative Myeloma in T‐Cell Receptor‐Transgenic Mice. Scandinavian Journal of Immunology. 60(1-2). 143–152. 3 indexed citations
4.
Lundin, Katrin U., Valentina Screpanti, Hilde Omholt, et al.. (2004). CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunology Immunotherapy. 53(12). 1135–1145. 22 indexed citations
5.
Lundin, Katrin U., Peter O. Hofgaard, Hilde Omholt, et al.. (2003). Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood. 102(2). 605–612. 35 indexed citations
6.
Dellacasagrande, Jérôme, Olav Schreurs, Peter O. Hofgaard, et al.. (2003). Liver Metastasis of Cancer Facilitated by Chemokine Receptor CCR6. Scandinavian Journal of Immunology. 57(6). 534–544. 60 indexed citations
7.
Bogen, Bjarne, Ludvig A. Munthe, Peter O. Hofgaard, et al.. (1995). Naive CD4+ T cells confer idiotype‐specific tumor resistance in the absence of antibodies. European Journal of Immunology. 25(11). 3079–3086. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026